How to buy Galera Therapeutics stock

Galera Therapeutics, Inc is a biotechnology business based in the US. Galera Therapeutics shares (GRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Galera Therapeutics employs 38 staff and has a market cap (total outstanding shares value) of 0.00.

Galera Therapeutics share price

Use our graph to track the performance of GRTX stocks over time.

Galera Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$6.15 - $15.00
50-day moving average	$8.95
200-day moving average	$10.48
Wall St. target price	$19.60
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.40

Buy Galera Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Galera Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Galera Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Galera Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-42.51%
Return on equity TTM	-196.02%
Profit margin	0%
Book value	N/A
Market capitalisation	$165.1 million

TTM: trailing 12 months

Shorting Galera Therapeutics shares

There are currently 160,601 Galera Therapeutics shares held short by investors – that's known as Galera Therapeutics's "short interest". This figure is 4.8% up from 153,228 last month.

There are a few different ways that this level of interest in shorting Galera Therapeutics shares can be evaluated.

Galera Therapeutics's "short interest ratio" (SIR)

Galera Therapeutics's "short interest ratio" (SIR) is the quantity of Galera Therapeutics shares currently shorted divided by the average quantity of Galera Therapeutics shares traded daily (recently around 70439.035087719). Galera Therapeutics's SIR currently stands at 2.28. In other words for every 100,000 Galera Therapeutics shares traded daily on the market, roughly 2280 shares are currently held short.

However Galera Therapeutics's short interest can also be evaluated against the total number of Galera Therapeutics shares, or, against the total number of tradable Galera Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galera Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Galera Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0217% of the tradable shares (for every 100,000 tradable Galera Therapeutics shares, roughly 22 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Galera Therapeutics.

Find out more about how you can short Galera Therapeutics stock.

Galera Therapeutics share dividends

We're not expecting Galera Therapeutics to pay a dividend over the next 12 months.

Galera Therapeutics overview

Galera Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. .

Frequently asked questions

What percentage of Galera Therapeutics is owned by insiders or institutions?
Currently 11.543% of Galera Therapeutics shares are held by insiders and 76.387% by institutions. How many people work for Galera Therapeutics?
Latest data suggests 38 work at Galera Therapeutics. When does the fiscal year end for Galera Therapeutics?
Galera Therapeutics's fiscal year ends in December. Where is Galera Therapeutics based?
Galera Therapeutics's address is: 2 West Liberty Boulevard, Malvern, PA, United States, 19355 What is Galera Therapeutics's ISIN number?
Galera Therapeutics's international securities identification number is: US36338D1081 What is Galera Therapeutics's CUSIP number?
Galera Therapeutics's Committee on Uniform Securities Identification Procedures number is: 36338D108